eRegister's captcha

Patent Register Details

Print page icon Print this page

PATENT REGISTER
A Supplementary Protection Certificate (SPC) exists for this Patent. To view the SPC Details click following SPC number(s): 2003/014 2005/001 2014/050 2014/053
Status Expired Patent No. 0720599
Application No. 94928563.9 Date of Filing 14/09/1994
Date Grant Published 19/05/1999 Application Published 21/03/1995
Title of Invention HYDROXY-SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS
Priority
Priority Country Filing Date Application No.
 United States of America  21/09/1993  102440
 United States of America  09/06/1994  257593
Inventors ROSENBLUM, Stuart, B.
DUGAR, Sundeep
BURNETT, Duane, A.
CLADER, John, W.
MCKITTRICK, Brian, A.
Patent Granted to SCHERING CORPORATION
2000 Galloping Hill Road
Kenilworth, NJ 07030
UNITED STATES OF AMERICA
Current Proprietor Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway
New Jersey 07065
UNITED STATES OF AMERICA
Address for service TOMKINS & CO.
5 Dartmouth Road
Dublin 6
IRELAND
Renewal Fees
Year Date Renewed
 20  29/08/2013
 19  29/08/2012
 18  26/08/2011
 17  16/08/2010
 16  23/07/2009
 15  18/07/2008
 14  13/07/2007
 13  20/07/2006
 12  30/06/2005
 11  14/07/2004
 10  29/07/2003
 9  22/07/2002
 8  20/07/2001
 7  10/08/2000
 6  31/08/1999
Publication Language English
Translation Received Date
06/11/2003 Request for grant a Supplementary Protection Certificate, citing Patent number 0720599 as the relevent basic patent, in respect of the product Ezetimibe or a pharmaceutically acceptable salt thereof. filed on 30/10/2003. Reference number of request is 2003/014.
27/01/2005 Request for grant a Supplementary Protection Certificate, citing Patent number 0720599 as the relevent basic patent, in respect of the product Ezetimibe, or a pharmaceutically acceptable salt therof, in combination with a cholesterol biosynthesis inhibitor such as simvastatin. filed on 21/01/2005. Reference number of request is 2005/001.
03/08/2005 Supplementary Protection Certificate Number 2003/014, having an expiry date of 16/10/2017 granted on 03/08/2005.
03/08/2005 Supplementary Protection Certificate Number 2005/001, having an expiry date of 01/04/2019 granted on 03/08/2005.
19/07/2012 Change of name and address of proprietor from SCHERING CORPORATION, 2000 Galloping Hill Road, Kenilworth, NJ 07030, United States of America to Merck Sharp & Dohme Corp., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States of America recorded on 12/07/12.
15/09/2014 Request for grant a Supplementary Protection Certificate, citing Patent number 0720599 as the relevant basic patent, in respect of the product Ezetimibe and rosuvastatin or pharmaceutically acceptable salts thereof, including rosuvastatin as a zinc salt filed on 11/09/2014. Reference number of request is 2014/050.
17/09/2014 Request for grant a Supplementary Protection Certificate, citing Patent number 0720599 as the relevant basic patent, in respect of the product ezetimibe and atorvastatin or pharmaceutically acceptable salts thereof, including atorvastatin as atorvastatin calcium trihydrate filed on 12/09/2014. Reference number of request is 2014/053.
13/10/2014 Patent expired on 13/09/2014.
24/08/2015 Application for an extension of the duration of Supplementary Protection Certificate No. 2003/014 filed on 22/07/2015.
16/06/2016 Application for an extension of the duration of Supplementary Protection Certificate No. 2003/014 granted on 16/06/2016. New expiry date of Supplementary Protection Certificate, as extended, is 16/04/2018.
22/05/2017 Request for grant of Supplementary Protection Certification No. 2014/050 rejected in respect of Article 10(2) of Regulation (EC) No. 469/2009
03/03/2021 Supplementary Protection Certificate No. 2005/001 revoked by Order of the High Court dated 29 November 2019.